risperidone


Also found in: Medical, Wikipedia.

ris·per·i·done

 (rĭ-spĕr′ə-dōn′)
n.
An oral antipsychotic drug, C28H27FN4O2, that is a dopamine and serotonin antagonist and is used to treat schizophrenia and bipolar disorder.

[Perhaps (fluo)r(obenz)is(oxazole), one of its constituents (fluoro- + benz- + is(o)- + ox- + azole) + (pi)perid(ine) + -one.]
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.
Translations

risperidone

n risperidona
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
References in periodicals archive ?
6,667,061, arising from the defendants' filing of an NDA with the FDA seeking approval to market defendants' extended release risperidone injections before the expiration patent protection on Risperdal Consta.
Currently, risperidone is one of the atypical antipsychotics for the most severe schizophrenia patients because of its excellent effects.
Objective: To compare frequency of Hyperprolactinemia with Risperidone and Olanzapine in patients with first episode psychosis.
(2) Although risperidone is one of the more widely used antipsychotics for treating schizophrenia, until recently the only available LAI preparation, risperidone microspheres (Risperdal Consta), required 3 weeks of oral coverage upon initiation.
In this case, we present a child diagnosed with relapsed Wilm's tumour, who developed EPS just after a short duration of initiation of risperidone prescribed as an appetite stimulant.
Pharmaceutical company Indivior PLC (LON:INDV) reported on Monday the launch of the US Food and Drug Administration (FDA) approved PERSERIS (risperidone) first once-monthly for extended-release injectable suspension in the US for the treatment of schizophrenia in adults.
Background: Risperidone and paliperidone have been the mainstay treatment for schizophrenia and their potential role in neuroprotection could be associated with brain-derived neurotrophic factor (BDNF) and N400 (an event-related brain potential component).
Participants were randomized to one of three antipsychotics commonly used in children with disruptive behavioral disorders -- oral aripiprazole (49 patients), olanzapine (46 patients), or risperidone (49 patients) -- and were evaluated for 12 weeks.
However to the best of our knowledge, there has been no report in literature for the worsening of MG due to oral risperidone treatment.
Clozapine, olanzapine, and oral and long-acting injectable formulations of risperidone proved superior on more schizophrenia outcomes that did other second-generation antipsychotics, according to a review of the effectiveness of treatments for adults with the illness.
[10] More interestingly, some studies showed the SNP (single nucleotide polymorphism) subtypes, rs4795893, rs1024611, rs4586 and rs2857657, of CCL2, the coding gene of MCP-1, were associated with treatment resistance of risperidone in the Han Chinese population.